Literature DB >> 22388664

Active surveillance in prostate cancer: patient selection and triggers for intervention.

Kathryn Lees1, Meeta Durve, Chris Parker.   

Abstract

PURPOSE OF REVIEW: The long-term safety and effectiveness of active surveillance depends on our ability to select appropriate patients and trigger delayed treatment in those who need it, whereas avoiding intervention in those who do not. In this review, we will consider how recent advances have influenced patient selection for active surveillance and review the range of different intervention triggers that have been proposed. RECENT
FINDINGS: Several large surveillance cohort studies have been reported recently showing excellent medium-term outcomes in well selected patients, with approximately a third of patients going on to have deferred treatment. Debate continues on the most appropriate eligibility criteria for active surveillance and what triggers for intervention should be used. There is growing interest in the role of transperineal template biopsies and multiparametric MRI, both for patient selection and in identifying triggers for intervention.
SUMMARY: Active surveillance is a well tolerated treatment option in well selected groups of patients. There is no 'one size fits all' set of criteria for patient selection or triggers for intervention but decisions can be guided by information from histology, prostate-specific antigen kinetics and imaging.

Entities:  

Mesh:

Year:  2012        PMID: 22388664     DOI: 10.1097/MOU.0b013e328351dc47

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  6 in total

Review 1.  Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification.

Authors:  Stacy Loeb; Sophie M Bruinsma; Joseph Nicholson; Alberto Briganti; Tom Pickles; Yoshiyuki Kakehi; Sigrid V Carlsson; Monique J Roobol
Journal:  Eur Urol       Date:  2014-10-31       Impact factor: 20.096

2.  Predictors of pathological upgrading in low-risk prostate cancer patients without hypointense lesions on an apparent diffusion coefficient map of multiparametric magnetic resonance imaging.

Authors:  Minyong Kang; Byeongdo Song; Injae Lee; Sang Eun Lee; Seok-Soo Byun; Sung Kyu Hong
Journal:  World J Urol       Date:  2016-04-13       Impact factor: 4.226

3.  Seventh Joint Meeting of K-J-CaP and CaPSURE: extending the global initiative to improve prostate cancer management.

Authors:  Hideyuki Akaza; Choung Soo Kim; Peter Carroll; In Young Choi; Byung Ha Chung; Matthew R Cooperberg; Yoshihiko Hirao; Shiro Hinotsu; Shigeo Horie; Ji Youl Lee; Mikio Namiki; Chi-Fai Ng; Mizuki Onozawa; Seiichiro Ozono; Satoru Ueno; Rainy Umbas; Dingwei Ye; Gang Zhu
Journal:  Prostate Int       Date:  2014-06-30

4.  Predicting clinically significant prostate cancer based on pre-operative patient profile and serum biomarkers.

Authors:  Izak Faiena; Sinae Kim; Nicholas Farber; Young Suk Kwon; Brian Shinder; Neal Patel; Amirali H Salmasi; Thomas Jang; Eric A Singer; Wun-Jae Kim; Isaac Y Kim
Journal:  Oncotarget       Date:  2017-09-28

5.  PSMA as a target for radiolabelled small molecules.

Authors:  Matthias Eder; Michael Eisenhut; John Babich; Uwe Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-06       Impact factor: 9.236

6.  The accuracy of prostate cancer localization diagnosed on transrectal ultrasound-guided biopsy compared to 3-dimensional transperineal approach.

Authors:  Kevin Krughoff; Khadijah Eid; Jason Phillips; Diliana Stoimenova; Daniel Smith; Colin O'Donnell; E David Crawford; Al Barqawi
Journal:  Adv Urol       Date:  2013-12-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.